Clinical Trial Update: A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight [Phase 2]

View source ↗

Summary

A Phase 2b trial evaluating once-weekly MET097 for safety and efficacy in adults with obesity, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• MET097

Snippet

Sponsor: Metsera, a wholly owned subsidiary of Pfizer | Conditions: Obesity, Overweight or Obesity | Phase 2 | Status: ACTIVE_NOT_RECRUITING